Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00646425 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis
A Phase 2 study, sponsored by Cerimon Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00646425 is a Phase 2 study that was terminated before completion, run by Cerimon Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT00646425, a Phase 2 study, was terminated before completion, sponsored by Cerimon Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.
Interventions
- DRUG Placebo
- DRUG Basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2008-05 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00646425
The ClinicalTrials.gov registry entry for NCT00646425 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerimon Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00646425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00646425 about?
NCT00646425 is a clinical study titled "The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis". The objective of this trial is to assess if treatment with basiliximab allows subjects to taper off other immunosuppressive drug regimens without causing an increase in their uveitis.
What is the current status of trial NCT00646425?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2008-05. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00646425?
The interventions under investigation include: Placebo (DRUG), Basiliximab (DRUG).
Who is sponsoring clinical trial NCT00646425?
This trial is sponsored by Cerimon Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.